Post-Remission Therapy

Post-Remission Therapy in Leukemia

Purpose

• After induction achieves complete remission (CR) (morphologic clearance of blasts), the goal is to eradicate residual disease (MRD) and prevent relapse.
• Therapy intensity and components differ by leukemia type.

Acute Lymphoblastic Leukemia (ALL)

Phases After Induction

1. Consolidation / Intensification
   • Multiple cycles of multi-agent chemotherapy.
   • Agents: high-dose methotrexate, cytarabine, cyclophosphamide, asparaginase, anthracyclines, mercaptopurine, vincristine, corticosteroids, ± blinatumomab (in some modern protocols like ECOG1910).
   • Goal: deepen remission, eliminate MRD.
2. Maintenance
   • Daily 6-mercaptopurine (oral)
   • Weekly methotrexate (oral or IV)
   • ± pulses of vincristine and prednisone every 4–12 weeks
   • Duration: ~2–3 years (longer in children).
3. CNS Prophylaxis
   • Intrathecal (IT) chemotherapy (methotrexate ± cytarabine + hydrocortisone).
   • Sometimes systemic high-dose MTX or Ara-C.
   • Goal: prevent CNS relapse.
4. Targeted / Immunotherapy (selected patients)
   • Blinatumomab: for MRD+ patients after induction/consolidation.
   • Inotuzumab: in relapsed/refractory settings, being explored in consolidation.
   • CAR T-cell therapy: mainly in relapse but under investigation for frontline post-remission use.
5. Allogeneic HSCT
   • Indicated for high-risk subgroups (e.g., adults with persistent MRD, adverse cytogenetics, relapsed disease).

Acute Myeloid Leukemia (AML)

Post-Remission Options

1. Consolidation Chemotherapy
   • High-dose cytarabine (HiDAC):
     • Adults <60: 3 g/m² IV q12h on days 1, 3, 5 (up to 3–4 cycles).
     • Older/unfit: reduced-intensity cytarabine or intermediate-dose.
2. Targeted Therapy
   • FLT3 inhibitors (midostaurin, gilteritinib, sorafenib) added in FLT3-mutated AML.
   • IDH inhibitors (enasidenib, ivosidenib) sometimes in consolidation/maintenance for IDH-mut AML.
3. Allogeneic HSCT
   • Standard for intermediate or adverse-risk AML in CR1 (first remission).
   • Post-remission transplant decisions are based on cytogenetics, molecular markers, MRD status, age, comorbidities.
4. Maintenance Therapy
   • Oral azacitidine (CC-486): approved for maintenance in older AML patients post-remission (QUAZAR AML-001 trial).
   • FLT3 inhibitors (e.g., sorafenib) sometimes used as post-HSCT maintenance in FLT3-mut AML.

Key Oncology Pharmacy Points

• ALL: Post-remission includes consolidation + maintenance + CNS prophylaxis ± HSCT ± immunotherapy (blinatumomab, CAR T).
• AML: Post-remission = consolidation with HiDAC or allo-HSCT, and increasingly maintenance with targeted agents or hypomethylating drugs.
• MRD status is increasingly driving decisions (e.g., blinatumomab in MRD+ ALL, transplant referral in MRD+ AML).